文献速递膀胱癌与上尿路尿路上皮癌

上尿路尿路上皮癌的综合基因组特征分析

Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.
PubMed 文献 · Eur Urol · 2017-06-07

本研究对来自两家机构的31例未治疗上尿路尿路上皮癌(UTUC)样本进行全外显子测序、RNA测序和蛋白分析,鉴定出FGFR3、KMT2D、PIK3CA和TP53等基因突变及四种具有不同临床特征的分子亚型,并发现一种新的SH3KBP1-CNTNAP5融合。

要点

  • UTUC中FGFR3突变频率为74.1%,其中低级别为92%,高级别为60%。
  • RNA测序聚类分析识别出四种分子亚型,各亚型在突变谱、吸烟史、肿瘤分级分期和复发模式上存在差异。
  • 发现一种新的SH3KBP1-CNTNAP5融合,可能调控RTK信号通路。

核心结论

  • UTUC的基因突变频率与膀胱癌不同,存在四种独特的分子和临床亚型,并发现一种新的SH3KBP1融合可能调控RTK信号通路。

研究设计与样本

  • 研究收集了来自两家机构的31例未治疗新鲜冷冻UTUC样本,进行了全外显子测序(WES)、RNA测序(RNAseq)和蛋白分析。

主要发现

  • WES鉴定出FGFR3突变(74.1%;低级别92%,高级别60%)、KMT2D突变(44.4%)、PIK3CA突变(25.9%)和TP53突变(22.2%)。
  • APOBEC和CpG是最常见的突变特征。
  • RNAseq数据的非监督共识层次聚类(UCHC)将样本分为四个分子亚型:Cluster 1无PIK3CA突变、非吸烟者、高级别<pT2肿瘤、高复发;Cluster 2为100% FGFR3突变、低级别肿瘤、吸烟、非浸润性疾病、无膀胱复发;Cluster 3为100% FGFR3突变、71% PIK3CA突变、无TP53突变、5例膀胱复发、吸烟、所有肿瘤<pT2;Cluster 4为KMT2D(62.5%)、FGFR3(50%)、TP53(50%)突变、无PIK3CA突变、高级别pT2+疾病、吸烟、原位癌、较短生存期。
  • 发现一种新的SH3KBP1-CNTNAP5融合。

局限性

  • 需要进一步研究来验证所描述的亚型、探索其对治疗的反应并更好地定义新的融合突变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Upper urinary tract urothelial cancer (UTUC) may have unique etiologic and genomic factors compared to bladder cancer. OBJECTIVE: To characterize the genomic landscape of UTUC and provide insights into its biology using comprehensive integrated genomic analyses. DESIGN, SETTING, AND PARTICIPANTS: We collected 31 untreated snap-frozen UTUC samples from two institutions and carried out whole-exome sequencing (WES) of DNA, RNA sequencing (RNAseq), and protein analysis. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Adjusting for batch effects, consensus mutation calls from independent pipelines identified DNA mutations, gene expression clusters using unsupervised consensus hierarchical clustering (UCHC), and protein expression levels that were correlated with relevant clinical variables, The Cancer Genome Atlas, and other published data. RESULTS AND LIMITATIONS: WES identified mutations in FGFR3 (74.1%; 92% low-grade, 60% high-grade), KMT2D (44.4%), PIK3CA (25.9%), and TP53 (22.2%). APOBEC and CpG were the most common mutational signatures. UCHC of RNAseq data segregated samples into four molecular subtypes with the following characteristics. Cluster 1: no PIK3CA mutations, nonsmokers, high-grade <pT2 tumors, high recurrences. Cluster 2: 100% FGFR3 mutations, low-grade tumors, tobacco use, noninvasive disease, no bladder recurrences. Cluster 3: 100% FGFR3 mutations, 71% PIK3CA, no TP53 mutations, five bladder recurrences, tobacco use, tumors all <pT2. Cluster 4: KMT2D (62.5%), FGFR3 (50%), TP53 (50%) mutations, no PIK3CA mutations, high-grade pT2+ disease, tobacco use, carcinoma in situ, shorter survival. We identified a novel SH3KBP1-CNTNAP5 fusion. CONCLUSIONS: Mutations in UTUC occur at differing frequencies from bladder cancer, with four unique molecular and clinical subtypes. A novel SH3KBP1 fusion regulates RTK signaling. Further studies are needed to validate the described subtypes, explore their responses to therapy, and better define the novel fusion mutation. PATIENT SUMMARY: We conducted a comprehensive study of the genetics of upper urinary tract urothelial cancer by evaluating DNA, RNA and protein expression in 31 tumors. We identified four molecular subtypes with distinct behaviors. Future studies will determine if these subtypes appear to have different responses to treatments.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Moss TJ, Qi Y, Xi L, et al. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol. 2017. PMID: 28601352. doi:10.1016/j.eururo.2017.05.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。